ERBB2 and metastatic neoplasm: In a paper published in the current special issue, our group reported on the systemic delivery of the HER2-retargeted ReHV named R-337, its blood clearance and biodistribution, and its anticancer efficacy against lung cancer, a model of metastatic disease [22].